An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [14C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis

Trial Profile

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [14C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Etelcalcetide (Primary)
  • Indications Secondary hyperparathyroidism
  • Focus Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 30 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 31 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top